Novartis’ TREM2 drug fails Phase 2 ALS trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis’ TREM2 drug fails Phase 2 ALS trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Reuters, Fierce Biotech, Investor's Business Daily and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 4h ago.
Quick answers
Why is "Novartis’ TREM2 drug fails Phase 2 ALS trial" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Novartis halts ALS drug development after mid-stage trial failure Reuters · 10h ago
- Novartis ends ALS program after phase 2 flop, adding to R&D woes Fierce Biotech · 10h ago
- Novartis Suffers Another Setback After Stock-Rocking Failures Investor's Business Daily · 10h ago
- Novartis Experimental Drug for ALS Fails in Another Pipeline Hit Bloomberg.com · 10h ago
- Novartis’ TREM2 drug fails Phase 2 ALS trial Endpoints News · 10h ago
Topics
Related trends
Novartis ends ALS program after phase 2 flop, adding to R&D woes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Vera kidney drug Trutakna shows strong final results in Phase 3 trial
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Chris Johnson unable to travel to Nashville, Titans postpone Ring of Honor ceremony
The Tennessee Titans postponed Chris Johnson's Ring of Honor ceremony as the former running back battles ALS.
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A Promising Heart Drug Failed. What Went So Wrong?
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.